PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Saturday, June 1, 2013

AllTrials contd. - D Day for comments - June 10th

Posted on 3:26 AM by Unknown

HRA ANNOUNCES PLANS FOR PROMOTING TRANSPARENCY AROUND PUBLICATION OF HEALTH RESEARCH FINDINGS

The Health Research Authority (HRA) has today outlined plans for how it will play a leading role in ensuring clinical and other health research findings are published Transparency in health research has long been a subject of debate; recently, the House of Commons Science and Technology Committee has launched an enquiry into Clinical Trials and the high-profile Alltrials campaign has attracted tens of thousands of signatures. The HRA has an established role to promote transparency, and already publishes research study summaries and the opinions of its Research Ethics Committees (RECs). On 25 April, the HRA led a stakeholder workshop, at which it made, with the full support of its partners, a number of commitments, which are now being sent out for further comment.

These include proposals:
 To make the registration of clinical trials within an agreed timeframe a condition of REC approval from September 2013.
 To work with research funders and sponsors to set standards for the publication and dissemination of research outcomes.
 To develop mechanisms to actively review plans for publication against these standards and include them specifically within the condition of the REC approval.
 To develop simple mechanisms to monitor compliance with REC approved plans to publish  To set standards and issue guidance for how those that have participated in research are appropriately informed of individual outcomes and study results at the end
 To work with regulators of professions to address the misconduct of withholding results.
 Work with publishers to dispel the myths and perceptions about the difficulties in publishing results.

The HRA will work with partners to turn these commitments into actions, and welcomes further views on the plans.

Welcoming the paper, Janet Wisely, HRA Chief Executive, said “We have long supported the sharing of all health research findings, have already signed up to the Alltrials.net petition and publish a summary and the research opinion for research projects which come before our Research Ethics Committees. We have encouraged wider debate on the subject through our Stakeholder Forum in February and our recent workshop with representatives of patient-facing organisations, researchers and industry. Change will only come through determined leadership and, with the commitment of our partners to increasing openness, we are now sharing our plans for promoting transparency in a robust and sustainable way. We have also been mindful of our ambition to make it easier to do good quality research in the UK and have set out sensible and proportionate measures that will increase transparency and increase confidence in health research in the UK.

 Ben Goldacre, AllTrials campaign said, “We have known for decades that the results of clinical trials are routinely withheld in medicine. This is one of the most important ethical and practical problems facing medicine today. Some have tried to hide from it: the HRA are demonstrating clear leadership, with impressive and solid practical suggestions. I hope that all in medicine will give the HRA their wholehearted support”.

Iain Chalmers, Coordinator of the James Lind Initiative added 'The HRA's paper 'Transparent Research' is evidence of a welcome ambition to improve research registration, publication, data access and participant information. I endorse the HRA's approach and urge researchers, research participants and the public in general to support the HRA's proposals.’

Simon Denegri, Chair of INVOLVE, added 'I very much welcome this robust and comprehensive statement of intent by the HRA to improve research transparency. Past and future participants in research studies should be encouraged by the firm commitment to look at this agenda from a public and patient angle. In particular, the emphasis on providing the right information in the right way and at the right time has an important bearing on people's access to, and willingness to take part in, research. I look forward to working with the HRA in taking these recommendations forward and ensuring that there is strong public involvement in their development.'

http://www.hra.nhs.uk/hra-news-and-announcements/transparent-research/
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ►  July (104)
    • ▼  June (81)
      • China detains GlaxoSmithKline staff for fraud: rep...
      • Get in the sack
      • Tamiflu saga continues - NYT. By Katie Thomas
      • Gouging the patient - 1boringoldman explains
      • Deen dumped
      • FDA shuts down 1,677 online pharmacies
      • Treasure Ireland contd.
      • SEC charges medical imaging firm CEO for lying on ...
      • Sleepy Seroquel
      • Federal lawmakers urge FDA to change rules to allo...
      • #UMNProud
      • Nemeroff in London - let's see the slides
      • Pfizer still on the asbestos hook
      • Meet the new Mr NICE Guy
      • Of the 86 drugs in the industry's diabetes pipelin...
      • Sometimes it is best to do nothing. A "must read "...
      • Evidence Based Medicine - Why we can’t trust clini...
      • Pharmaceutical scandal: 'You pay us £300. However,...
      • SCANDAL
      • Who's who at Quantum Pharmaceuticals?
      • Busted! No Solace for Quantum
      • Saying no to chemotherapy by Des Spence - BMJ
      • For you - special price!
      • Zalcrap contd.
      • Your puny western ads don't work on our Russian wo...
      • UK plans to cut some drug prices by up to 20 per cent
      • A Fistful of Dollars - The Cephalon off label way
      • A Smoking Pillbox: Evidence that Sgt. Bales May Ha...
      • Nine pharmas fined by EU
      • Jagemeister PR - you're doing it wrong
      • For AZ's Onglyza SAVOUR is not a saviour
      • EU fines Lundbeck for paying off pharma rivals
      • Young Law Group Announces Initiative Prosecuting A...
      • FDA Probes Deaths Linked to Long-Acting Zyprexa
      • A holy mess
      • J&J buy Aragon
      • Introducing polypill.com - medication for the mass...
      • FT - Professor turns to internet to distribute pol...
      • Shire Pharmaceuticals Ltd and Roche Products Limit...
      • NIH Censoring Expert to Prevent Criticism of Ethic...
      • Merck announces it will slash jobs at research lab...
      • AllTrials - the countdown begins
      • Experts Propose Restoring Invisible And Abandoned ...
      • The Painful Politics of Painkillers Opioids are de...
      • GSK - Little Trouble in Big China
      • No dishonour in depression
      • Healing the Overwhelmed Physician - by Jerry Avorn
      • GlaxoSmithKline Fires China R&D Boss for 'Misrepre...
      • Charles Nemeroff - Honoured in Britain, the US psy...
      • How Big Pharma Drives Up Medicare Spending Without...
      • Walgreens pays record $80 million settlement for i...
      • Has pancreatic damage from glucagon suppressing di...
      • Austerity is bull!
      • Obama administration reverses course on Plan B pill
      • Corporate Whistle Blower Center Now Urges Pharmace...
      • Endo Implodes
      • Introducing OTC Toolbox
      • Pearl bought
      • Johnson & Johnson seeks home court advantage in Ty...
      • The geography of antidepressant, antipsychotic, an...
      • One to watch - Dispatches, Channel 4, Monday June ...
      • How much is your doctor making from Big Pharma?
      • Not just Bad - Ineffective Pharma!
      • Not just Bad - Filthy Pharma
      • Big data to sniff out drug marketing fraud
      • Dr Sidney Wolfe retires with a bang!
      • Kerching!
      • No-user, no cry
      • Nine pharma firms face EU fines over pay-for-delay...
      • Here for a good time or a long time?
      • Yet another J&J recall!
      • The Myth of the New
      • Keepy-uppy!
      • Meet the Doctor Big Pharma Can't Shut Up
      • In Memoriam: Barbara A. Brenner, 1951-2013
      • Pink Ribbons Inc. - watch the movie
      • Gouging 101 spotted by Dr Judy Stone
      • Summer Reading contd. Blood Medicine by Kathleen S...
      • Corporate fines are puny
      • "Brad Abbey" on Ben Goldacre
      • AllTrials contd. - D Day for comments - June 10th
    • ►  May (5)
Powered by Blogger.